RNAZ ▲ +10.8% - TransCode Therapeutics, Inc.
$RNAZ RNAZ - TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
28-OCT-2026 04:30 PM ET
Share this post
More filings for $RNAZ
RNAZ ▲ +1.7% - TransCode Therapeutics, Inc.Oct 26, 2026RNAZ ▼ -1.8% - TransCode Therapeutics, Inc.Oct 19, 2026RNAZ ▼ -5.9% - TransCode Therapeutics, Inc.Sep 28, 2026RNAZ ▲ +6.8% - TransCode Therapeutics, Inc.Sep 22, 2026RNAZ ▼ -7.3% - TransCode Therapeutics, Inc.Sep 10, 2026RNAZ ▲ +16.6% - TransCode Therapeutics, Inc.Aug 31, 2026
View full $RNAZ filing history →💬 Comments
Loading comments…
Leave a comment